Cleveland Clinic | Strategic Alliance Partners
Cleveland Clinic is a nonprofit multispecialty academic medical center that integrates clinical and hospital care with research and education. Located in Cleveland, Ohio, it was founded in 1921 by four renowned physicians with a vision of providing outstanding patient care based upon the principles of cooperation, compassion and innovation. Cleveland Clinic has pioneered many medical breakthroughs, including coronary artery bypass surgery and the first face transplant in the United States. Cleveland Clinic is consistently recognized in the U.S. and throughout the world for its expertise and care. Among Cleveland Clinic’s 81,000 employees worldwide are more than 5,743 salaried physicians and researchers, and 20,160 registered nurses and advanced practice providers, representing 140 medical specialties and subspecialties. Cleveland Clinic is a 6,690-bed health system that includes a 173-acre main campus near downtown Cleveland, 23 hospitals, 276 outpatient facilities, including locations in northeast Ohio; Florida; Las Vegas, Nevada; Toronto, Canada; Abu Dhabi, UAE; and London, England. In 2023, there were 13.7 million outpatient encounters, 323,000 hospital admissions and observations, and 301,000 surgeries and procedures throughout Cleveland Clinic’s health system. Patients came for treatment from every state and 132 countries. Visit us at clevelandclinic.org. Follow us at twitter.com/CleClinicNews. News and resources available at newsroom.clevelandclinic.org.
Editor’s Note: Cleveland Clinic News Service is available to provide broadcast-quality interviews and B-roll upon request.rt.
Latest from Cleveland Clinic
Building Trust and Increasing Patient Engagement With MS Communities: Marisa McGinley, DO
February 27th 2023At the 2023 ACTRIMS Forum, the staff neurologist from the Mellen Center for MS Treatment and Research at the Cleveland Clinic talked about the lack of trust and engaging more with the MS community. [WATCH TIME: 5 minutes]
Access to MS Care in Underserved and Diverse Populations: Marisa McGinley, DO
February 26th 2023The staff neurologist at the Mellen Center for MS Treatment and Research at Cleveland Clinic, spoke at the 2023 ACTRIMS Forum about disparities in care access for patients with MS. [WATCH TIME: 5 minutes]
Expanding the Window to Use Mechanical Thrombectomy, Treat Ischemic Stroke: Gabor Toth, MD
February 17th 2023The vascular and interventional neurologist at Cleveland Clinic provided insight on a study presented at the 2023 International Stroke Conference that observed the clinical effectiveness of mechanical thrombectomy beyond 24 hours. [WATCH TIME: 6 minutes]
Advantages to Directly Transferring Stroke Treatment to Angiography: Shazam Hussain, MD, FRCP, FAHA
February 14th 2023The director of Cleveland Clinic’s Cerebrovascular Center discussed the decisions mobile stroke units face and why opting for direct transfer to angiography is meant for certain scenarios. [WATCH TIME: 3 minutes]
NeuroVoices: Shumei Man, MD, on How Collaboration Between Hospitals Reduces Readmission for Stroke
February 8th 2023The medical director of stroke at Fairview Hospital, an affiliate of Cleveland Clinic, provided perspective on a new intervention that improves communication and reduces hospital readmission for stroke.
Linking the Latest Research to Clinical Care in MS: Robert Bermel, MD
December 19th 2022The director of the Mellen Center for MS at Cleveland Clinic offered an overview of the State of the Science Summit that was held on November 10, 2022, featuring a panel of expert clinicians. [WATCH TIME: 4 minutes]
Chronic ASM Use Associated With Acute Symptomatic Seizures in Patients With Stroke
December 6th 2022Retrospective analysis of a group of individuals with stroke suggests that nonconvulsive acute symptomatic seizures are associated with long-term use of antiseizure medications, providing key data in guiding therapy use in this population.
Future Thoughts on Improving MS Trial Design, Calculations: Carrie Hersh, DO, MSc
November 23rd 2022The associate professor of neurology at the Cleveland Clinic Lerner College of Medicine provided perspective on how the clinical community can improve trials for multiple sclerosis that help improve treatment decisions. [WATCH TIME: 4 minutes]
Establishing a Proof Of Concept Model to Improve MS Treatment Optimization: Carrie Hersh, DO, MSc
November 14th 2022The associate professor of neurology at the Cleveland Clinic Lerner College of Medicine offered insight on her presentation at ECTRIMS 2022 looking at 2-stage models to better understand heterogeneous treatment effects of MS DMTs. [WATCH TIME: 6 minutes]
Telehealth and Digital Measures May Assist With Monitoring MS Progression: Marisa McGinley, DO
November 7th 2022The staff neurologist at the Mellen Center for MS Treatment and Research at Cleveland Clinic spoke about her presentation from ECTRIMS 2022 on teleneurology and its utilization as a tool to make care more accessible to patients with MS. [WATCH TIME: 7 minutes]
Advocacy in Neurology: A Tool to Serve and Find Fulfillment
November 7th 2022Acting as an advocate is meaningful to neurologists because it speaks to their inner core—or their “why.” Neurologists have the agency to make this world a better place while working as a neurologist and an advocate at many levels.
Teleneurology Overcomes Health Disparities and Improves Accessibility in MS: Marisa McGinley, DO
November 6th 2022The staff neurologist at the Mellen Center for MS Treatment and Research at Cleveland Clinic, spoke about her presentation on teleneurology being a beneficial healthcare tool for patients with MS at ECTRIMS 2022. [WATCH TIME: 7 minutes]
Ofatumumab’s Effect on Annualized Relapse Rate in Patients with MS: Jeffrey Cohen, MD
October 28th 2022The neurologist in the Mellen Center for Multiple Sclerosis Treatment and Research at Cleveland Clinic, shares more on his late breaker presentation from the 38th ECTRIMS conference. [WATCH TIME: 4 minutes]
NurOwn Treatment Shows Positive Results in Phase 2 Study of Progressive Multiple Sclerosis
September 16th 2022Treatment with NurOwn resulted in response on several secondary outcomes, including timed 25-foot walk, 12-item multiple sclerosis walking scale, and low contrast letter acuity, among others.
NeuroVoices: Lynn Bekris, PhD, on sTREM2 and GFAP to Differentiate Cognitive Status, Trajectory
September 7th 2022The molecular biologist at the Cleveland Clinic Lerner Research Institute provided commentary on how certain activity markers may help understand immune response differences in Alzheimer disease and related dementias.
Future Research and Questions Surrounding GFAP, sTREM2 in Alzheimer Disease: Lynn Bekris, PhD
August 24th 2022The molecular biologist at the Cleveland Clinic Lerner Research Institute provided insight on the lingering questions about GFAP and sTREM2 astrocytes, and their immunologic correlations with Alzheimer disease and related dementias. [WATCH TIME: 4 minutes]
